bpc 157 for tendon repair healing BPC-157 – Peptide • Muscle & healing • Joint pain & inflammation The Science Behind BPC-157: Injury

Always consult your healthcare provider before starting any supplement

Blood tests may be used to look for common and treatable contributors

this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults

This triple-receptor mechanism is designed to produce significant reductions in body weight and improvements in metabolic parameters

Frequently Asked Questions About BPC-157 in Canada What Should a Certificate of Analysis Include for BPC-157